Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPK-002
- Development stage
- Preclinical
- Lead developer
- EPIK Biosciences
- Modality
- Small Molecules
- Administration
- Intravenous, Sublingual, Topical
01
Overview
EPK-002 is a ketamine-based small molecule combination medicine in development by EPIK Biosciences. It is designed to modulate NMDA receptor signaling through a synergistic combination formulation, consistent with EPIK's broader platform of proprietary ketamine-based and NMDA receptor-targeting therapies. The drug is intended to treat conditions including depression, anxiety disorders, post-traumatic stress disorder (PTSD), opioid use disorder, and chronic or severe pain. EPK-002 is currently in the IND-enabling stage of development.
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on EPK-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPK-002.